This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cao, Y. Articles by Dewhirst, M. W. Search for Related Content PubMed PubMed Citation Articles by Cao, Y. Articles by Dewhirst, M. W.

Observation of Incipient Tumor Angiogenesis That Is Independent of Hypoxia and Hypoxia Inducible Factor-1 Activation

Departments of ¹ Pathology, ² Radiation Oncology, ³ Medicine, ⁴ Biostatistics and Bioinformatics, and ⁵ Biomedical Engineering, Duke University Medical Center, Durham, North Carolina

Requests for reprints: Mark W. Dewhirst, Department of Radiation Oncology, Duke University Medical Center, MSRB Room 201, Research Drive, DUMC 3455, Durham, NC 27710. Phone: 919-684-4180; Fax: 919-684-8718; E-mail: dewhirst{at}radonc.duke.edu.

It is well established that hypoxia potently stimulates tumor angiogenesis by activating hypoxia inducible factor-1 (HIF-1)–induced proangiogenic factors, such as vascular endothelial growth factor. However, very little is known about the role of hypoxia in incipient angiogenesis in avascular tumors during their early stages of growth. To noninvasively investigate the functional significance of hypoxia and HIF-1 activation in incipient tumor angiogenesis, we genetically engineered HCT116 human colon carcinoma cells and 4T1 mouse mammary carcinoma cells with constitutively expressed red fluorescence protein as a tumor marker and green fluorescence protein (GFP) as a reporter for hypoxia and HIF-1 activation. The accuracy of GFP fluorescence in reporting hypoxia was confirmed by flow cytometry analysis and by immunohistochemical comparison with pimonidazole, a well-established hypoxia marker drug. Mouse dorsal skin-fold window chambers showed that incipient angiogenesis preceded a detectable level of hypoxia. The detectable levels of hypoxia were spatially and temporally related with more intensive secondary angiogenesis following the initial onset of new vessel formation. Selective killing of hypoxic cells by tirapazamine efficiently eliminated or delayed the detection of hypoxic cells, but it did not significantly delay the onset of incipient angiogenesis. These findings provide the first in vivo evidence that incipient tumor angiogenesis may not depend on hypoxia or HIF-1 activation. This is in contrast to the clear role of hypoxia in driving angiogenesis once initial tumor microvessel formation has occurred.

This article has been cited by other articles:

				B. A Teicher Tumor Models for Efficacy Determination Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 571 - 585. [Abstract] [Full Text] [PDF]

				D. A. Torigian, S. S. Huang, M. Houseni, and A. Alavi Functional Imaging of Cancer with Emphasis on Molecular Techniques CA Cancer J Clin, July 1, 2007; 57(4): 206 - 224. [Abstract] [Full Text] [PDF]

				Y. Cao, P. Sonveaux, S. Liu, Y. Zhao, J. Mi, B. M. Clary, C.-Y. Li, C. D. Kontos, and M. W. Dewhirst Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth Cancer Res., April 15, 2007; 67(8): 3835 - 3844. [Abstract] [Full Text] [PDF]

				V. Raman, D. Artemov, A. P. Pathak, P. T. Winnard Jr., S. McNutt, A. Yudina, A. Bogdanov Jr., and Z. M. Bhujwalla Characterizing Vascular Parameters in Hypoxic Regions: A Combined Magnetic Resonance and Optical Imaging Study of a Human Prostate Cancer Model. Cancer Res., October 15, 2006; 66(20): 9929 - 9936. [Abstract] [Full Text] [PDF]

				B. A. Teicher Tumor models for efficacy determination. Mol. Cancer Ther., October 1, 2006; 5(10): 2435 - 2443. [Abstract] [Full Text] [PDF]

				U. Emmenegger, G. C. Morton, G. Francia, Y. Shaked, M. Franco, A. Weinerman, S. Man, and R. S. Kerbel Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia Cancer Res., February 1, 2006; 66(3): 1664 - 1674. [Abstract] [Full Text] [PDF]